Mood stabilization via central nervous system modulation

The phrase "Mood stabilization via central nervous system modulation" refers to the use of pharmacological agents—most notably mood stabilizers such as lithium, valproate, carbamazepine, and lamotrigine—to alter signaling pathways, neurotransmitter systems, and neurotrophic factors in the brain with the goal of preventing or reducing the severity of mood episodes in neuropsychiatric disorders such as bipolar disorder and depression. These agents act on a variety of molecular targets, including but not limited to inositol monophosphatase, voltage-gated sodium channels, GABAergic and glutamatergic pathways, and intracellular signaling elements like CREB, GSK-3, and brain-derived neurotrophic factor. Therefore, the phrase does not represent a single druggable target but rather a therapeutic domain encompassing a network of molecular targets within the central nervous system[1][2][4][5][6]. This entry should not be used as a canonical molecule or receptor record. For structured data and target mapping, it is essential to identify the specific molecule(s) or protein target(s) mediating mood stabilization in the central nervous system—such as "Inositol monophosphatase" for lithium, or "Voltage-gated sodium channel" for carbamazepine.

Inositol depletion (lithium, valproate, carbamazepine); Modulation of GABA and glutamate transmission; Blockade of voltage-gated sodium channels (carbamazepine, lamotrigine); Inhibition of inositol monophosphatase (lithium); Modulation of signal transduction pathways (e.g., cAMP, CREB, GSK-3, BDNF); Neuroprotection and neurogenesis